Support for advanced-therapy developers

25 juin 2019

BlueRegWatch

Developers of advanced therapy medicinal products (ATMPs) must be aware of the legislation governing different stages of the medicine development process, including good manufacturing practice (GMP), good clinical practice (GCP) and good laboratory practice (GLP) requirements. The European Medicines Agency (EMA) offers a range of advisory services and incentives to support the development of ATMPs.

BlueRegWatch

Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :

Découvrez notre dernier livre blanc

En savoir plus